Novartis Gains Approval for First Infant Malaria Treatment, Promising Hope for Vulnerable Babies
Novartis has received approval for the first malaria treatment designed specifically for newborns and infants, offering new hope in the global fight against malaria, especially in African countries with high mortality rates.
In a significant breakthrough in malaria treatment, Swiss pharmaceutical company Novartis has received approval from Swiss health regulators for the first medication specifically designed for newborns and young infants suffering from malaria. Collaborating with the Medicines for Malaria Venture (MMV), Novartis developed an age-appropriate version of its well-known Coartem (Riamet) therapy, intended for babies weighing between two to five kilograms (roughly 4.4 to 11 pounds). Until now, there were no approved treatments tailored for infants weighing less than 4.5 kilograms, leaving a vulnerable population at risk.
Malaria remains a devastating disease worldwide, particularly in Africa where the continent accounted for 95% of the 597,000 global deaths from malaria in 2023, as reported by the World Health Organization. Children under five years old suffered the majority, with over 76%, or more than 432,000 deaths. The new treatment aims to fill this critical gap by providing an approved, safe, and effective option for this high-risk group.
The approval process involved eight of the hardest-hit African countries—Burkina Faso, Ivory Coast, Kenya, Malawi, Mozambique, Nigeria, Tanzania, and Uganda—which are now expected to quickly adopt and distribute the new medication under a program designed to enhance access for low- and middle-income countries. Novartis has committed to providing the treatment on a largely not-for-profit basis to improve healthcare access in malaria-endemic regions.
This development comes at a crucial time, as the fight against malaria faces funding challenges. Despite the progress, global funding levels are threatened by political decisions, notably those linked to US foreign aid policies, which previously financed approximately 40% of malaria control efforts worldwide. The World Health Organization estimates that 263 million people still suffered from malaria in 2023, underscoring the urgent need for innovative and accessible treatments.
The approval of this infant-specific therapy marks a hopeful step forward in reducing childhood mortality from malaria and represents a vital addition to global health initiatives aimed at combating this preventable and treatable disease.
[Source: https://medicalxpress.com/news/2025-07-infant-malaria-treatment-novartis.html]
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Unveiling the Impact of Senescent Cells on Aging at the Single-Cell Level
New research reveals how senescent cells influence tissue aging and dysfunction through complex interactions uncovered at the single-cell level in vivo. These findings provide critical insights into the role of cellular senescence in aging and age-related diseases.
Updated Guidelines Emphasize Asking Diabetic Women About Pregnancy Intentions at Every Healthcare Visit
New guidelines recommend healthcare providers routinely discuss pregnancy intentions with women managing diabetes during every medical visit to improve preconception care and reduce risks.
Parents Support Early HPV Vaccination for Children at Age 9 or 10
A new study reveals that most parents and clinicians are receptive to administering the HPV vaccine to children at ages 9 or 10, potentially improving vaccination rates and cancer prevention efforts.
Guidelines Recommend SGLT-2 and GLP-1 Therapies Primarily for Adults at Elevated Risk of Heart and Kidney Issues
New international guidelines recommend using SGLT-2 inhibitors and GLP-1 receptor agonists mainly for adults with type 2 diabetes at moderate or high risk of heart and kidney complications, supporting personalized treatment approaches.